Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15644331 | 0.76 | NUDT1 (0.35) | KDM4EKMT2ALMNAMAOBMAPT | |
| SCHEMBL30494729 | 0.74 | KDM4E (0.51) | KDM4ECYP1A2KMT2AMEN1ALPG | |
| SCHEMBL31038760 | 0.71 | KDM4E (0.39) | KDM4ECYP1A2KMT2AMEN1ALPG | |
| SCHEMBL11662489 | 0.68 | CYP1A2 (0.39) | KDM4ECYP1A2KMT2AMEN1ALPG | |
| SCHEMBL17574484 | 0.68 | MAOB (0.39) | KDM4EKMT2AMEN1HTTLMNA | |
| SCHEMBL16684965 | 0.67 | MAOB (0.44) | KDM4EKMT2AHTTLMNAMAOB | |
| SCHEMBL31212696 | 0.67 | CYP1A2 (0.44) | KDM4ECYP1A2KMT2AMEN1ALPG | |
| SCHEMBL3787340 | 0.64 | HTT (0.49) | KDM4ECYP1A2KMT2AMEN1ALPG | |
| SCHEMBL13738007 | 0.64 | JAK1 (0.47) | KDM4ECYP1A2KMT2AMEN1ALPG | |
| SCHEMBL11195631 | 0.64 | MAPT (0.57) | KDM4EKMT2AMEN1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200254041-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | RECEPTOR HOLDINGS, INC. (US) | 2020-08-13 | — | — | US | claimed |
| EP-3672610-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | Receptor Holdings, Inc. (US) | 2020-07-01 | — | — | EP | claimed |
| EP-3565539-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | Receptor Holdings, Inc. (US) | 2019-11-13 | — | — | EP | claimed |
| US-20190336472-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2019-11-07 | — | — | US | claimed |
| WO-2019071213-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | RECEPTOR LIFE SCIENCES, INC. (US) | 2019-04-11 | — | — | WO | claimed |
| WO-2018129097-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR LIFE SCIENCES (US) | 2018-07-12 | — | — | WO | claimed |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | Doane Technology Group LLC (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250268861-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | SPOKE SCIENCES, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12303487-B2 | N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions | SPOKE SCIENCES, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250152509-A1 | PARTICLES, AQUEOUS DISPERSIONS, AND LIQUID COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | SPOKE SCIENCES, INC. (US) | 2025-05-15 | — | — | US | disclosed |
| WO-2025090945-A1 | FORMULATIONS HAVING A GLYCOSIDE AND A LIPOPHILIC COMPONENT | SPOKE SCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| EP-4440556-A2 | PARTICLES, AQUEOUS DISPERSIONS, AND LIQUID COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | Spoke Sciences, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240261303-A1 | PARTICLES, AQUEOUS DISPERSIONS, AND COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | SPOKE SCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-2139333-A4 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20100029697-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| US-20100029697-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| EP-2139333-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-2139333-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008118414-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118414-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029697-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, FAAH | KDM4E 1920/4885CYP1A2 745/4885KMT2A 3051/4885 |
| US-20250152509-A1 | PARTICLES, AQUEOUS DISPERSIONS, AND LIQUID COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | NAPEPLD, CNR1, CNR2 | KDM4E 4528/4885CYP1A2 1154/4885KMT2A 4471/4885 |
| US-20250268861-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | FAAH, CNR2, FABP2 | KDM4E 1931/4885CYP1A2 593/4885KMT2A 1713/4885 |
| US-20200254041-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | FAAH, CNR1, GPR18 | KDM4E 1328/4885CYP1A2 534/4885KMT2A 1353/4885 |
| US-12303487-B2 | N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions | FAAH, CNR2, FABP2 | KDM4E 1931/4885CYP1A2 593/4885KMT2A 1713/4885 |
| US-20190336472-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | GPR18, SLC1A5, CNR2 | KDM4E 2063/4885CYP1A2 605/4885KMT2A 1981/4885 |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | CNR2, CNR1, LIPC | KDM4E 3730/4885CYP1A2 1304/4885KMT2A 4708/4885 |
| US-20240261303-A1 | PARTICLES, AQUEOUS DISPERSIONS, AND COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | LIPA, PLIN3, LPL | KDM4E 4857/4885CYP1A2 1956/4885KMT2A 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.